Sanofi has offered public corrections and limits on promotional claims after the Commission raised concerns that it disparaged CSL Seqirus’s Fluad vaccine, extending EU competition enforcement into the way dominant pharmaceutical companies communicate with health professionals.
Sanofi has offered binding commitments to address European Commission concerns that it disparaged a rival influenza vaccine in France and Germany, turning a dispute over medical promotion into a test of EU abuse-of-dominance law.
The case concerns Sanofi’s Efluelda vaccine and Fluad, an enhanced influenza vaccine made by CSL Seqirus. Both are used for older or vulnerable patients, making recommendations by national immunisation bodies commercially important.
The Commission’s preliminary view is that Sanofi may hold a dominant position in enhanced influenza vaccines in the two national markets and may have used misleading communication to restrict competition.
What Sanofi has offered
Under the proposed commitments, Sanofi would publish statements on its French and German websites reflecting national expert assessments of the two vaccines. It would also change promotional communications and avoid portraying Fluad negatively or suggesting unsupported superiority for Efluelda.
The Commission’s notice on the commitments invites comments from interested parties by 21 August. If accepted, the commitments would remain in force until March 2030.
Sanofi says offering commitments does not amount to an admission of infringement and maintains that it complied with applicable law. The Commission has likewise not made a final finding.
Why disparagement can be an antitrust issue
Companies are normally free to argue that their product is better. Competition law becomes relevant when a dominant company allegedly uses misleading or denigrating claims to exclude a rival rather than competing on evidence, price and quality.
Healthcare markets are especially sensitive because prescribers and public authorities rely on scientific information that manufacturers help provide. A distorted message can affect recommendations, purchasing decisions and patient access long before a court or regulator establishes what happened.
The Commission formally opened its Sanofi investigation on 26 June. The rapid move to commitments suggests both sides see value in correcting market information before a long infringement proceeding concludes.
Commitments offer speed but less precedent
An Article 9 commitments decision can make promises legally binding without requiring the Commission to prove an infringement. Breaching them can lead to substantial fines.
The advantage is speed. Health authorities and clinicians receive clarifying information while the relevant vaccination market is active. The disadvantage is that a commitments decision provides less legal guidance than a fully contested abuse finding.
That matters because pharmaceutical disparagement cases are becoming an identifiable line of EU enforcement. Companies need to know where robust scientific disagreement ends and exclusionary conduct begins.
The theory differs from the self-preferencing conduct examined in EU Today’s coverage of the Commission’s Google adtech abuse decision, but both cases use Article 102 to examine how a dominant company can distort the route through which customers encounter competing products.
Competition policy enters the clinic
The case does not ask Brussels to decide which vaccine is medically superior. It asks whether a company with potential market power communicated about its rival in a way that unlawfully restricted competition.
National technical advisory groups remain responsible for vaccine recommendations, while medicines regulators assess safety, quality and efficacy. Competition authorities examine whether the market around those decisions remains open and undistorted.
For health systems, the stakes include price, supply resilience and choice. If one supplier can weaken a rival through misleading claims, procurement may become more concentrated and vulnerable. If regulators police ordinary scientific debate too aggressively, companies may become reluctant to communicate legitimate evidence.
The Commission’s market test will help determine whether Sanofi’s proposed corrections are clear, durable and capable of restoring competition. It also signals to the wider pharmaceutical sector that promotional conduct can attract the same Article 102 scrutiny as pricing, exclusivity or access restrictions.
